Molecular Diagnosis & Therapy

, Volume 18, Issue 4, pp 409–418 | Cite as

Tumor Cellularity as a Quality Assurance Measure for Accurate Clinical Detection of BRAF Mutations in Melanoma

  • Jonathan C. Dudley
  • Grzegorz T. Gurda
  • Li-Hui Tseng
  • Derek A. Anderson
  • Guoli Chen
  • Janis M. Taube
  • Christopher D. Gocke
  • James R. Eshleman
  • Ming-Tseh LinEmail author
Original Research Article



Detection of BRAF mutations is an established standard of care to predict small-molecule inhibitor (vemurafenib) response in metastatic melanoma. Molecular assays should be designed to detect not only the most common p.V600E mutation, but also p.V600K and other non-p.V600E mutations.


The purpose of this study was to assess if tumor cellularity can function as a quality assurance (QA) measure in molecular diagnostics. Potential causes of discrepancy between the observed and predicted mutant allele percentage were also explored.


We correlated pathologist-generated estimates of tumor cellularity versus mutant allele percentage via pyrosequencing as a QA measure for BRAF mutation detection in formalin-fixed, paraffin-embedded melanoma specimens.


BRAF mutations were seen in 27/62 (44 %) specimens, with 93 % p.V600E and 7 % non-p.V600E. Correlation between p.V600E mutant percentage and tumor cellularity was poor–moderate (r = −0.02; p = 0.8), primarily because six samples showed a low p.V600E signal despite high tumor cellularity. A QA investigation revealed that our initial pyrosequencing assay showed a false positive, weak p.V600E signal in specimens with a p.V600K mutation. A redesigned assay detected BRAF mutations in 50/131 (38 %) specimens, including 30 % non-p.V600E. This revised assay showed strong correlation between p.V600E BRAF mutant percentage and tumor cellularity (r = 0.76; p ≤ 0.01). Re-evaluation of the previously discordant samples by the revised assay confirmed a high level of p.V600K mutation in five specimens.


Pathologists play important roles in molecular diagnostics, beyond identification of correct cells for testing. Accurate evaluation of tumor cellularity not only ensures sufficient material for required analytic sensitivity, but also provides an independent QA measure of the molecular assays.


Mutant Allele BRAF Mutation Vemurafenib Tumor Cellularity BRAF Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Acknowledgement and Disclosure

The authors have no conflicts of interest pertaining to this work. This work will be presented, in part, at the 103rd Annual Meeting of the United States and Canadian Academy of Pathology (USCAP) in San Diego, CA, USA, in March 2014. We would like to thank Molly Van Appledorn for statistical analysis consultation, and Norman J. Barker for assistance in generating figures.


  1. 1.
    Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.PubMedCrossRefGoogle Scholar
  2. 2.
    Kong Y, Kumar SM, Xu X. Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells. Arch Pathol Lab Med. 2010;134(12):1740–9.PubMedCentralPubMedGoogle Scholar
  3. 3.
    Roring M, Brummer T. Aberrant B-Raf signaling in human cancer: 10 years from bench to bedside. Crit Rev Oncog. 2012;17(1):97–121.PubMedCrossRefGoogle Scholar
  4. 4.
    Amanuel B, Grieu F, Kular J, Millward M, Iacopetta B. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology. 2012;44(4):357–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135–47.PubMedCrossRefGoogle Scholar
  6. 6.
    Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239–46.PubMedCrossRefGoogle Scholar
  7. 7.
    Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2011;17(2):229–35.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Ugurel S, Thirumaran RK, Bloethner S, Gast A, Sucker A, Mueller-Berghaus J, et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One. 2007;2(2):e236.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, et al. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn. 2013;15(2):220–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res. 2012;18(12):3242–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med. 2010;8:67.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596–9.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Klein O, Clements A, Menzies AM, O’Toole S, Kefford RF, Long GV. BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer. 2013;49(5):1073–9.PubMedCrossRefGoogle Scholar
  15. 15.
    McArthur G, Hauschild A, Robert C, Larkin J, Haanen JB, Ribas A, et al. Efficacy of vemurafenib in BRAFV600K mutation-positive melanoma disease: results from phase 3 clinical study BRIM3. Pigment Cell Melanoma Res. 2012;25(6):871.Google Scholar
  16. 16.
    Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–14.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Ascierto PA, Minor D, Ribas A, Lebbe C, O’Hagan A, Arya N, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 2013;31(26):3205–11.PubMedCrossRefGoogle Scholar
  18. 18.
    Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(8):782–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379(9829):1893–901.PubMedCrossRefGoogle Scholar
  20. 20.
    Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14.PubMedCrossRefGoogle Scholar
  21. 21.
    Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65.PubMedCrossRefGoogle Scholar
  22. 22.
    Anderson S, Bloom KJ, Vallera DU, Rueschoff J, Meldrum C, Schilling R, et al. Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med. 2012;136(11):1385–91.PubMedCrossRefGoogle Scholar
  23. 23.
    Halait H, Demartin K, Shah S, Soviero S, Langland R, Cheng S, et al. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn Mol Pathol. 2012;21(1):1–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Qu K, Pan Q, Zhang X, Rodriguez L, Zhang K, Li H, et al. Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays. J Mol Diagn. 2013;15(6):790–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Fadhil W, Ibrahem S, Seth R, Ilyas M. Quick-multiplex-consensus (QMC)-PCR followed by high-resolution melting: a simple and robust method for mutation detection in formalin-fixed paraffin-embedded tissue. J Clin Pathol. 2010;63(2):134–40.PubMedCrossRefGoogle Scholar
  26. 26.
    Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809–19.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Kotoula V, Charalambous E, Biesmans B, Malousi A, Vrettou E, Fountzilas G, et al. Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One. 2009;4(11):e7746.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Tan YH, Liu Y, Eu KW, Ang PW, Li WQ, Salto-Tellez M, et al. Detection of BRAF V600E mutation by pyrosequencing. Pathology. 2008;40(3):295–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Lin MT, Tseng LH, Rich RG, Hafez MJ, Harada S, Murphy KM, et al. Delta-PCR, a simple method to detect translocations and insertion/deletion mutations. J Mol Diagn. 2011;13(1):85–92.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Chen G, Olson MT, O’Neill A, Norris A, Beierl K, Harada S, et al. A virtual pyrogram generator to resolve complex pyrosequencing results. J Mol Diagn. 2012;14(2):149–59.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn. 2010;12(4):425–32.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Olson MT, Harrington C, Beierl K, Chen G, Thiess M, O’Neill A, Taube J, Zeiger MA, Lin MT, Eshleman JR. BRAF pyrosequencing analysis aided by a lookup table. Am J Clin Pathol. 2014 (in press)Google Scholar
  33. 33.
    Lin MT, Tseng LH, Beierl K, Hsieh A, Thiess M, Chase N, et al. Tandem duplication PCR: an ultrasensitive assay for the detection of internal tandem duplications of the FLT3 gene. Diagn Mol Pathol. 2013;22(3):149–55.PubMedCrossRefGoogle Scholar
  34. 34.
    Harada S, Henderson LB, Eshleman JR, Gocke CD, Burger P, Griffin CA, et al. Genomic changes in gliomas detected using single nucleotide polymorphism array in formalin-fixed, paraffin-embedded tissue: superior results compared with microsatellite analysis. J Mol Diagn. 2011;13(5):541–8.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Colomba E, Helias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, et al. Detection of BRAF p. V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn. 2013;15(1):94–100.PubMedCrossRefGoogle Scholar
  36. 36.
    Ihle MA, Fassunke J, Konig K, Grunewald I, Schlaak M, Kreuzberg N, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p. V600E and non-p.V600E BRAF mutations. BMC Cancer. 2014;14(1):13.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Mullins FM, Dietz L, Lay M, Zehnder JL, Ford J, Chun N, et al. Identification of an intronic single nucleotide polymorphism leading to allele dropout during validation of a CDH1 sequencing assay: implications for designing polymerase chain reaction-based assays. Genet Med. 2007;9(11):752–60.PubMedCrossRefGoogle Scholar
  38. 38.
    Schwartz KM, Pike-Buchanan LL, Muralidharan K, Redman JB, Wilson JA, Jarvis M, et al. Identification of cystic fibrosis variants by polymerase chain reaction/oligonucleotide ligation assay. J Mol Diagn. 2009;11(3):211–5.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Ward KJ, Ellard S, Yajnik CS, Frayling TM, Hattersley AT, Venigalla PN, et al. Allelic drop-out may occur with a primer binding site polymorphism for the commonly used RFLP assay for the -1131T>C polymorphism of the Apolipoprotein AV gene. Lipids Health Dis. 2006;5:11.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Lade-Keller J, Romer KM, Guldberg P, Riber-Hansen R, Hansen LL, Steiniche T, et al. Evaluation of BRAF mutation testing methodologies in formalin-fixed, paraffin-embedded cutaneous melanomas. J Mol Diagn. 2013;15(1):70–80.PubMedCrossRefGoogle Scholar
  41. 41.
    Magnin S, Viel E, Baraquin A, Valmary-Degano S, Kantelip B, Pretet JL, et al. A multiplex SNaPshot assay as a rapid method for detecting KRAS and BRAF mutations in advanced colorectal cancers. J Mol Diagn. 2011;13(5):485–92.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    McCourt CM, McArt DG, Mills K, Catherwood MA, Maxwell P, Waugh DJ, et al. Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. PLoS One. 2013;8(7):e69604.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Rechsteiner M, von Teichman A, Ruschoff JH, Fankhauser N, Pestalozzi B, Schraml P, et al. KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics. J Mol Diagn. 2013;15(3):299–311.PubMedCrossRefGoogle Scholar
  44. 44.
    Szankasi P, Reading NS, Vaughn CP, Prchal JT, Bahler DW, Kelley TW. A quantitative allele-specific PCR test for the BRAF V600E mutation using a single heterozygous control plasmid for quantitation: a model for qPCR testing without standard curves. J Mol Diagn. 2013;15(2):248–54.PubMedCrossRefGoogle Scholar
  45. 45.
    Tuononen K, Maki-Nevala S, Sarhadi VK, Wirtanen A, Ronty M, Salmenkivi K, et al. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS. Genes Chromosomes Cancer. 2013;52(5):503–11.PubMedCrossRefGoogle Scholar
  46. 46.
    Busam KJ, Hedvat C, Pulitzer M, von Deimling A, Jungbluth AA. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Am J Surg Pathol. 2013;37(3):413–20.PubMedCrossRefGoogle Scholar
  47. 47.
    Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013;37(1):61–5.PubMedCrossRefGoogle Scholar
  48. 48.
    Routhier CA, Mochel MC, Lynch K, Dias-Santagata D, Louis DN, Hoang MP. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol. 2013;44(11):2563–70.PubMedCrossRefGoogle Scholar
  49. 49.
    Marin C, Beauchet A, Capper D, Zimmermann U, Julie C, Ilie M, et al. Detection of BRAF p. V600E mutations in melanoma by immunohistochemistry has a good interobserver reproducibility. Arch Pathol Lab Med. 2014;138(1):71–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Hoorens A, Jouret-Mourin A, Sempoux C, Demetter P, De Hertogh G, Teugels E. Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists. Acta Gastroenterol Belg. 2010;73(4):497–503.PubMedGoogle Scholar
  51. 51.
    van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008;453(5):417–31.PubMedCrossRefGoogle Scholar
  52. 52.
    Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, de Stricker K, et al. External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist. 2011;16(4):467–78.PubMedCentralPubMedCrossRefGoogle Scholar
  53. 53.
    Smits AJ, Kummer JA, de Bruin PC, Bol M, van den Tweel JG, Seldenrijk KA, et al. The estimation of tumor cell percentage for molecular testing by pathologists is not accurate. Mod Pathol. 2014;27(2):168–74.Google Scholar
  54. 54.
    Viray H, Li K, Long TA, Vasalos P, Bridge JA, Jennings LJ, et al. A prospective, multi-institutional diagnostic trial to determine pathologist accuracy in estimation of percentage of malignant cells. Arch Pathol Lab Med. 2013;137(11):1545–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Boissiere-Michot F, Lopez-Crapez E, Frugier H, Berthe ML, Ho-Pun-Cheung A, Assenat E, et al. KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment. Mod Pathol. 2012;25(5):731–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Ondrejka SL, Schaeffer DF, Jakubowski MA, Owen DA, Bronner MP. Does neoadjuvant therapy alter KRAS and/or MSI results in rectal adenocarcinoma testing? Am J Surg Pathol. 2011;35(9):1327–30.PubMedCrossRefGoogle Scholar
  57. 57.
    Viray H, Coulter M, Li K, Lane K, Madan A, Mitchell K, et al. Automated objective determination of percentage of malignant nuclei for mutation testing. Appl Immunohistochem Mol Morphol (Epub 24 Oct 2013).Google Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Jonathan C. Dudley
    • 1
  • Grzegorz T. Gurda
    • 1
  • Li-Hui Tseng
    • 1
    • 2
  • Derek A. Anderson
    • 1
  • Guoli Chen
    • 1
  • Janis M. Taube
    • 1
  • Christopher D. Gocke
    • 1
    • 3
  • James R. Eshleman
    • 1
    • 3
  • Ming-Tseh Lin
    • 1
    Email author
  1. 1.Department of PathologyJohns Hopkins University School of Medicine, Johns Hopkins HospitalBaltimoreUSA
  2. 2.Department of Medical GeneticsNational Taiwan University HospitalTaipeiTaiwan
  3. 3.Department of OncologyJohns Hopkins University School of Medicine, Johns Hopkins HospitalBaltimoreUSA

Personalised recommendations